Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FGH31 (Compound 24), a dopamine D4 agonist, exhibits potent and selective GRK2-dependency with a K i of 1.6 nM and partially activates β-arrestin [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | FGH31 (Compound 24), a dopamine D4 agonist, exhibits potent and selective GRK2-dependency with a K i of 1.6 nM and partially activates β-arrestin [1]. |
Targets&IC50 | Dopamine D4 receptor:1.6 nM (Ki) |
In vitro | Compound FGH31 (50 μM) exhibits a rate of decline in rat liver microsomes comparable to that of Imipramine [1]. Additionally, there is no evidence of P-glycoprotein (P-gp) mediated transport of FGH31 (50 μM, 4 h) in Caco-2 cells [1]. |
Molecular Weight | 520.66 |
Formula | C33H36N4O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FGH31 GPCR/G Protein Neuroscience Dopamine Receptor inhibitor inhibit